Is cryoablation a viable alternative to surgery for early-stage breast cancer?

Question

Accepted Answer

Cryoablation Shows Promise as a Minimally Invasive Alternative for Select Early-Stage Breast Cancers, But Long-Term Efficacy Remains Under Investigation

Cryoablation presents a potentially viable, minimally invasive alternative to traditional surgery for certain early-stage breast cancers, offering the advantage of preserving breast structure and minimising scarring. However, its long-term efficacy and safety are still subjects of ongoing research, and it is not yet considered a routine treatment option outside of clinical trials for most patients. The procedure involves using extreme cold, between -40°C and -170°C, to destroy cancerous cells by inserting a cryoprobe directly into the tumour.
Cryoablation Offers a Less Invasive Approach

Cryoablation is a procedure that utilises extreme cold to destroy diseased cells, with temperatures ranging from -40°C to -170°C. It is a minimally invasive technique, often performed as day surgery, which takes approximately 30 minutes. During the process, a cryoprobe is inserted into the cancerous tumour, and a cooling gas is then circulated to freeze and eliminate the targeted tissue. This method aims to preserve the overall structure of the breast, thereby minimising scarring and potential deformities compared to surgical excision.
Patient Selection is Crucial for Cryoablation Suitability

Medical professionals consider cryoablation for specific cases of early-stage breast cancer, typically involving small tumours less than 1.5cm in size, confined to a single area, and exhibiting non-aggressive characteristics without signs of spread beyond the breast. It may also be an option for individuals who cannot safely undergo surgery due to age or co-existing health conditions, or when other local tumour control treatments are not available. However, the therapy is generally not recommended for aggressive tumours, ill-defined diseases, or patients under the age of 50.
Short-Term Data Suggests Comparable Recurrence Rates to Surgery

Current short-term data, extending up to five years of follow-up, indicates that cryoablation exhibits recurrence rates of approximately 1%, which are comparable to those seen with surgical lumpectomy. The procedure is generally well-tolerated, with minimal side effects reported, and rare instances of minor complications like frostbite have been noted. Promising results from institutions like Changi General Hospital have shown no evidence of residual tumours or recurrence in treated patients thus far.
Long-Term Data and Optimal Monitoring Protocols Are Still Developing

A significant limitation of cryoablation is the lack of extensive long-term data beyond five years, making patient selection paramount to ensure optimal outcomes and avoid compromising survival chances with established treatments. While some researchers hypothesise that cryoablation might stimulate the immune system to target cancer cells, acting as an "auto-vaccine," this potential benefit requires further study and confirmation. The precise methods for optimal monitoring and follow-up for patients treated with cryoablation are also not yet definitively established, and oncologic safety remains a primary concern.

Reading history

Hide →

This history is cleared when the page is closed.

Is cryoablation a viable alternative to surgery for early-stage breast cancer?

Loading

Was this article helpful?

Helpful

Not helpful

Report an issue

1

0

0

Share with friends